Christopher Von Seggern stepped down as Chief Commercial Officer of Xenon Pharmaceuticals Inc. and departed from the company. In connection with his departure ...

Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch ...

State Street Corp’s holdings in Xenon Pharmaceuticals were worth $11,004,000 at the end of the most recent quarter. Other hedge funds have also modified their holdings of the company.

Xenon's discovery concluded an intense period of research on noble gases. Much heavier than neon and krypton, it had not been explicitly predicted, and was sufficiently rare to avoid chance detection ...